Pinealon: Side Effects

Safety Notice#

The safety profile of Pinealon in humans has not been established through controlled clinical trials. The information below is derived primarily from animal studies and should be interpreted accordingly.

Documented Adverse Effects#

Objective: Summarize documented adverse effects and side effects for Pinealon (EDR; Glu‑Asp‑Arg) in animal studies and any human reports, including frequency and severity, and clearly distinguish animal vs human evidence.

Summary of available evidence

• Animal evidence (in vitro only): The peer‑reviewed study “Pinealon increases cell viability…” investigates Pinealon’s effects in rat cerebellar granule cells, rat neutrophils, and PC12 cells. It reports antioxidant and cytoprotective effects across 10–500 nM, with increased cell survival under oxidative stress and modulation of ERK1/2 and the cell cycle. No adverse effects, cytotoxicity attributable to Pinealon, LD50, NOAEL, or in vivo toxicity findings are reported in the accessible text. Thus, no animal adverse‑effect frequency or severity data are available from this source.

• Animal evidence (in vivo): Narrative monograph/review excerpts that discuss EDR/Pinealon describe neuroprotective effects in rodent models (e.g., Alzheimer’s disease, Huntington’s disease, prenatal hypoxia, hyperhomocysteinemia) and state that short peptides, including EDR, have “absence of side effects.” However, these texts do not provide quantitative toxicology metrics (no LD50/NOAEL), dosing, routes, or explicit adverse‑event listings. No frequency or severity data are provided (хавинсонUnknownyearббк28.072x12 pages 216-219, хавинсонUnknownyearббк28.072x12 pages 1-7).

• Human reports: Narrative sources claim oral administration of EDR/Pinealon has been used in athletes and older adults with statements that “no side effects” were observed. One additional non‑peer‑reviewed source provides general dosing recommendations but does not supply any systematic adverse‑event tables, nor frequency or severity grading. No clinical‑trial registry records with Pinealon as an intervention and adverse‑event reporting were found in our searches. Consequently, there are no extractable human adverse‑effect frequencies or severities from the retrieved evidence (holtorfUnknownyearfromuntreatableto pages 66-71, хавинсонUnknownyearббк28.072x12 pages 216-219, хавинсонUnknownyearббк28.072x12 pages 1-7).

What can be concluded about adverse effects, frequency, and severity

• Documented adverse effects: None explicitly documented for Pinealon in the retrieved sources. The in vitro study demonstrates protective effects and does not report Pinealon‑related toxicity; monograph/review excerpts state absence of side effects but without primary adverse‑event data.

• Frequency data: Not reported in any animal or human source located. No datasets with counts or percentages of adverse events were identified (holtorfUnknownyearfromuntreatableto pages 66-71, хавинсонUnknownyearббк28.072x12 pages 216-219, хавинсонUnknownyearббк28.072x12 pages 1-7).

• Severity data: Not reported. No CTCAE grades or equivalent severity classifications were found (holtorfUnknownyearfromuntreatableto pages 66-71, хавинсонUnknownyearббк28.072x12 pages 216-219, хавинсонUnknownyearббк28.072x12 pages 1-7).

• LD50/NOAEL or tolerability metrics: Not reported for Pinealon/EDR in the retrieved evidence.

Structured evidence snapshot

Limitations of the evidence base

• The strongest primary study identified is in vitro and does not address in vivo toxicity or safety endpoints.

• The additional sources that comment on “no side effects” are narrative/monograph‑type materials without accompanying quantitative adverse‑event data, dosing, or severity grading, and therefore cannot be used to estimate frequency or risk.

• No interventional human trials with Pinealon and reported adverse events were identified in the searched registry excerpts.

• Animal studies: No in vivo adverse‑effect data, frequencies, severities, LD50, or NOAEL for Pinealon were found; available in vitro data do not report toxicity and instead describe cytoprotective effects.

• Human reports: Only narrative claims of “no side effects”; no extractable adverse‑event frequency or severity data were identified in the retrieved sources (holtorfUnknownyearfromuntreatableto pages 66-71, хавинсонUnknownyearббк28.072x12 pages 216-219, хавинсонUnknownyearббк28.072x12 pages 1-7).

Contraindications#

Summary Pinealon (EDR; Glu‑Asp‑Arg) lacks formal, human-derived contraindication and drug–drug interaction data in the sources retrieved. Available evidence consists primarily of preclinical work and mechanistic modeling. Therefore, contraindications and interactions below are divided into: (a) reported/documented (none identified), and (b) theoretical, inferred from mechanisms of action and related peptide data.

Reported/documented

• Contraindications: None identified in retrieved literature or clinical registries for Pinealon/EDR.
• Drug–drug interactions: None documented.
• Adverse effects: No human adverse‑event reports found; preclinical studies report neuroprotective effects without toxicity reporting in the excerpts reviewed.
• Trial exclusion criteria: No human interventional trials of Pinealon were identified; thus, no standardized exclusion criteria were available.

Theoretical/mechanism-based interactions and cautions

• Epigenetic/gene regulation (promoter binding). Modeling indicates EDR forms low‑energy complexes with dsDNA motifs present in promoters of CASP3, NES, GAP43, APOE, SOD2, PPARA, PPARG. Potential pharmacodynamic interactions include: agents acting on PPAR pathways (e.g., thiazolidinediones, fibrates) and lipid metabolism modulators, given possible modulation of PPARA/PPARG and APOE.
• Neurotransmission and neuroplasticity. EDR prevented dendritic spine loss and tended to normalize LTP in AD mouse models, implying modulation of synaptic plasticity; prudence with CNS‑active drugs (antidepressants, antipsychotics, anticonvulsants, cognitive enhancers) due to potential additive or opposing effects on synaptic function.
• Oxidative stress pathways. Promoter association with SOD2 suggests modulation of antioxidant defenses; consider theoretical interactions with antioxidant supplements/therapies or pro‑oxidant chemotherapies.
• Apoptosis regulation. Promoter association with CASP3 implies influence on apoptosis; theoretical interactions with cytotoxic chemotherapy or apoptosis‑modulating agents.
• Vascular tone and endothelium. Related peptide data (e.g., KED) indicate effects on VEGF and endothelin‑1 and endothelial protection; broader short‑peptide literature notes normalization of coagulation and endothelial effects. Exercise caution alongside antihypertensives, vasodilators, or antithrombotics until human data clarify Pinealon’s vascular effects.
• Immune modulation. Short peptides have been reported to increase expression of receptors on T and B lymphocytes and enhance neutrophil phagocytic activity; consider caution with immunosuppressants and biologic immunomodulators.

Practice implications

• In the absence of human labeling or clinical interaction studies, Pinealon should be considered investigational with unknown contraindication/interaction profiles. Any use near critical therapies (anticoagulants, strong immunomodulators, PPAR‑active drugs, CNS polypharmacy, cytotoxic agents) warrants additional monitoring and shared decision‑making.

Limitations

• Evidence is preclinical and modeling-based; the exact mechanism of action remains uncertain and human pharmacokinetic/pharmacodynamic data are lacking.

Embedded summary

Toxicology#

Objective. We sought toxicological data for Pinealon (EDR; Glu-Asp-Arg), including LD50 values, organ toxicity studies, mutagenicity assays, and dose–response relationships.

Findings.

• LD50: No LD50 values were found in the retrieved literature for any species or route. The available peer‑reviewed source did not report acute lethality testing.
• Organ/system toxicity: No in vivo organ toxicity studies (subacute, subchronic, chronic, or specific organ histopathology/clinical chemistry) were identified in the retrieved sources.
• Mutagenicity/genotoxicity: No results from standard genotoxicity assays (Ames test, in vitro micronucleus, chromosome aberration, or comet assay) were found for Pinealon in the retrieved sources.
• Dose–response (in vitro): One peer‑reviewed study reported dose‑dependent cytoprotective and antioxidant effects in cell models. In rat cerebellar granule neurons and neutrophils, Pinealon reduced induced intracellular ROS in a concentration‑dependent manner; 100 nM prevented ouabain‑induced ROS accumulation and 500 nM abolished hydrocortisone‑induced (~92%) ROS elevation. In PC12 cells exposed to 1 mM H2O2 for 20 min (≈50% lethality), 60‑min preincubation with Pinealon produced concentration‑dependent protection, increasing cell survival and lowering ROS; Pinealon alone did not alter basal ROS. A 24‑h exposure to 50–500 nM shifted cell‑cycle distribution toward S/G2, consistent with proliferative modulation. Methods included DCF‑based ROS assays, chemiluminescence for neutrophils, Western blot (ERK1/2), and flow cytometry for cell cycle.

Interpretation. Based on retrieved evidence, published toxicology for Pinealon is limited to in vitro dose–response data demonstrating antioxidant/cytoprotective effects at nanomolar concentrations; we did not identify LD50, organ toxicity, or mutagenicity data. This represents a gap in the public toxicology record and indicates that formal safety characterization (OECD‑style acute, repeated‑dose, and genotoxicity batteries) is either unpublished or could not be located with our searches.

Summary table of available data:

Evidence Gaps#

• Human adverse event data is limited to anecdotal reports
• Systematic adverse event monitoring has not been conducted
• Drug interaction studies are incomplete
• Long-term safety profiles are unknown

Related Reading#

• Pinealon overview and research guide
• Pinealon dosing protocols
• Pinealon risks and legal status